Compare Lamb Weston Holdings Inc (LW) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs McKesson Corporation — how do they compare? Lamb Weston Holdings Inc trades at $47.87 (market cap $6.81B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 15.9× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays the higher dividend (3.07%). Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and McKesson Corporation for 74 Days on average.
| LW | MCK | |
|---|---|---|
Market Cap | $6.81B | $108.46B |
Volume | 4,638,686 | 712,607 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $995.69 |
52-Week Low | $38.48 | $725.17 |
Typical Hold Time | 66 Days | 74 Days |
Enterprise Value | $10.61B | $115.00B |
Dividend Yield | 3.07% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $49.46, up 2.85% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 14.17% ROE and trades at a P/E of 27.03. Recent news highlights cost-saving initiatives and anticipation for Q1 2026 earnings, while analyst consensus leans toward a hold with a $53.71 price target, suggesting modest upside from current levels.
Outlook remains cautiously optimistic given earnings momentum and operational improvements, but risks include margin pressure from rising costs and competitive threats. The stock's valuation appears fair relative to peers, with potential for growth if margin recovery continues, though investor confidence hinges on upcoming earnings results and execution of strategic initiatives.
McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
